Introduction {#sec1-1}
============

Acute kidney injury (AKI) resulting from glomerular hemorrhage has been described in patients with underlying kidney disease in the absence\[[@ref1][@ref2][@ref3]\] and presence\[[@ref4][@ref5]\] of coagulopathy (international normalized ratio \[INR\] of 6--9 range). More recently, AKI has been described among patients without underlying kidney disease and with more modest elevations of INR.\[[@ref6]\] The recognition of a characteristic histologic lesion that was associated with the clinical presentation of otherwise unexplained AKI in the setting of over-anticoagulation led to the term "anticoagulant-related nephropathy." We report a case of AKI with biopsy-proven anticoagulant-related nephropathy (ACRN) in a patient with mechanical heart valve where the anticoagulant therapy cannot be withheld.

Case Report {#sec1-2}
===========

A 50-year-old Indian female, who underwent mitral valve replacement for chronic rheumatic heart disease with severe mitral stenosis with left atrial appendicular clot, was on tablet acenocoumarol (Acitrom) 1 mg, tablet Ecosprin (aspirin) 75 mg, tablet Lanoxin (digoxin) 0.125 mg post mitral valve replacement for 2 years. She was on regular follow-up every 2 months and the dose of acenocoumarol was increased to 2 mg after 6 months. Her creatinine levels were within normal limits and INR within the therapeutic range. She had sudden abdominal distension with fever 1 year later and was diagnosed to have small bowel obstruction for which laparotomy with adhesiolysis was done. Tablet acenocoumarol 1 mg was started again postoperatively, which was increased to 2 mg in the next 6 months. Her creatinine levels were 0.9 and INR was within the therapeutic range. She had been on regular follow-up and was asymptomatic for a period of 1 year. She presented to us with the complaints of multiple episodes of non projectile, non-bilious vomiting following food intake and persistent high-colored urine for the past 1 month. There was no history of exertional dyspnea, chest pain, palpitations, and skin rashes. The patient did not complain of decreased urine output, dysuria, or pyuria. She was not a known diabetic or hypertensive. There was no significant past history with similar complaints. On physical examination, she was well nourished and moderately built, no evidence of pallor, pulse rate was 80 beats/min, and blood pressure was 110/60 mmHg. The patient had epigastric tenderness on abdominal palpation. Serum creatinine was 4.7 mg/dl, a 4-fold increase from her serum creatinine levels 6 months back, and INR was 4.70 (out of the therapeutic range) with dysmorphic red blood cells (RBCs) and casts in the urine. The provisional diagnosis of AKI in the background of anticoagulation was made and investigated further.

The autoimmune markers including anti-dsDNA antibodies, ANCA, and antinuclear antibodies were negative. The ultrasonography showed bilateral normal sized kidneys. Non-contrast computerized tomography confirmed bilateral normal-sized kidneys with no calculi, hydronephrosis, or retroperitoneal fibrosis. Renal biopsy was planned after switching over to heparin and achieving the therapeutic INR. Post biopsy, she was switched over to warfarin, and the target INR of 2 was achieved. The histology suggested acute tubulointerstitial nephritis with RBC casts \[[Figure 1](#F1){ref-type="fig"}\] and the immunofluorescence studies were negative. The patient was started on steroids. All the clinical investigations are shown in [Table 1](#T1){ref-type="table"}.

![Renal biopsy findings: tubules show intraluminal red cell casts. Interstitium shows infiltrate of lymphocytes and neutrophils](IJN-28-378-g001){#F1}
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Laboratory findings according to clinical phase and time

![](IJN-28-378-g002)

Discussion {#sec1-3}
==========

The diagnosis of ACRN should be suspected among patients who present with AKI in the setting of excessive anticoagulation and hematuria. A definitive diagnosis is made by renal biopsy. Incidence of AKI in the largest cohort of warfarin using patients was 20.5% overall and 33% in patients with a history of chronic kidney disease (CKD). Moderate or severe coagulopathy induced by warfarin or other anticoagulants, especially if INR \>4 and CKD, is the strongest risk factor for ACRN, and in these cases, prognosis is also worse than those without CKD. Other independent predictors of AKI risk in these patients were age, diabetes mellitus, heart failure, hypertension, and glomerulonephritis particularly with nephrotic syndrome.\[[@ref6][@ref7][@ref8]\] Kidney biopsy in a subset of these patients showed obstruction of the renal tubule by RBC casts, and this appears to be the dominant mechanism of AKI.\[[@ref6]\]

The initiating event in the pathogenesis of ACRN appears to be glomerular hemorrhage, caused by excessive anticoagulation due to warfarin or other anticoagulants.\[[@ref9]\] Glomerular hemorrhage results in the formation of obstructing RBC casts within the renal tubules. Obstructing intraluminal RBC casts are the most conspicuous histologic feature of ACRN in the tissue obtained from patients who have undergone biopsy\[[@ref10]\] and in animal models.\[[@ref11]\] The major histologic feature of ACRN is the obstruction of renal tubules (mainly distal) by RBC casts \[[Figure 1](#F1){ref-type="fig"}\].\[[@ref10]\] Even though disruption of the glomerular filtration barrier is the main pathophysiological event, the molecular mechanism is poorly determined. Proteinase-activated receptors which are activated by thrombin have trophic effect on endothelium; however, its role in the pathogenesis of ACRN is yet to be determined.\[[@ref12]\] The glomeruli show little or no abnormalities by immunofluorescence, light, or electron microscopy.

The management of warfarin-related nephropathy (WRN) in patients requiring prolonged anticoagulation poses a management dilemma. Alternative to warfarin, other anticoagulants such as dabigatran (direct thrombin inhibitor) and rivaroxaban, apixaban, and edoxaban (direct-activated factor X inhibitors) are being increasingly used. However, their renal safety is not established. In the literature, two cases of dabigatran-related nephropathy were reported.\[[@ref13][@ref14]\] Although RE-LY study showed that dabigatran was associated with smaller reductions in glomerular filtration rate compared to warfarin, its clinical significance is not clear, and most importantly, this study excluded those patients with estimated GFR (eGFR) of \<30 ml/min, which is the strongest risk factor for ACRN.\[[@ref15]\]

Brodsky *et al*. published a data of 9 patients of WRN. A total of 3 patients had complete renal recovery and 6 patients had partial/no renal recovery. All the three patients who recovered had normal eGFR 3 months before biopsy, and in the remaining 6 patients, eGFR was lower than normal. In our case, patient had normal baseline serum creatinine (0.9 mg/dl) before increasing warfarin dose, probably this could be the reason for complete renal recovery.\[[@ref10]\]

The role of steroids is not clear in WRN. The anti-inflammatory effect of steroids may be useful in mitigating the onset of interstitial fibrosis as a consequence of WRN. Temporary interruption of anticoagulation may ameliorate glomerular bleeding and result in stabilization of the renal function.\[[@ref16]\] We administered steroids in the present case and it should be tested in the future studies.

Conclusion {#sec1-4}
==========

Among patients who develop AKI and are on chronic anticoagulant therapy, a presumptive diagnosis of ACRN should be made if a severe coagulopathy is present and if other causes of AKI have been excluded. Renal biopsy may be warranted in different clinical setting. The most important measure to prevent ACRN is proper adjustment of the anticoagulant dose, especially in the CKD patients, who are more vulnerable to ACRN.
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